Chronic Myeloid Leukemia Coverage from Every Angle

Recent News

SOHO 2020: Indian Study of Protective Potential of Imatinib Against Malaria
SOHO 2020: Predicting Treatment-Free Remission With Nilotinib in Chronic-Phase CML
Do Associated Comorbidities Affect Oxidative Stress in CML?
Case Study: Does Hemodialysis Reduce Tyrosine Kinase Inhibitor Concentration in CML?
British Society for Haematology Guideline for Management of CML
Does Time to Response Impact Outcomes in Accelerated-Phase CML?
CML and COVID-19: Treatment Lessons Learned
Imatinib-Treated CML: A Contraindication to Renal Transplantation?
Canadian Study on Treatment Choices and Outcomes for Children With CML
CML AND COVID-19: Case Report of Successful Treatment With Tocilizumab
Medication Adherence and Its Effect on Molecular Response in CML
COVID-19 and CML: Case Report Involving Febrile Neutropenia and ARDS
UK TARGET CML Study: Comparing Real-World TKI Outcomes
Update From BYOND Trial of Bosutinib in Chronic-Phase CML
COVID-19 and CML: Patient Survey Results From China
Renal Toxicity in Patients With CML After Discontinuation of TKIs
EHA25 Virtual: Update on Second-Generation TKIs and Relapse in CML
Prevalence of Late Effects of TKIs in Patients With CML
EHA25 Virtual: Nilotinib Induction Therapy for Chronic Phase CML
EHA25 Virtual: Extended Follow-up on Early Switch From Imatinib to Dasatinib in CML
AACR II: Race-Based Survival Differences in Patients With CML Living in Texas
EHA25 Virtual: Nilotinib in Patients With CML Who Relapse After Discontinuing Imatinib
ASCO20: Are Providers Following Practice Guidelines for Discontinuation of TKIs?
EHA25 Virtual: Dose Reduction of Second-Generation TKIs in CML
EHA25 Virtual: Low-Dose Ponatinib for Patients With CML
Identifying Key Regulating Proteins in CML With CRISPR Technology
ASCO20: Long-Term Study Update on Bosutinib for Imatinib-Resistant CML
ASCO 2020: Early Results of Ponatinib Dose-Range Study in CML
ASCO20: Bosutinib for Patients With TKI-Intolerant CML
Is TKI Type Linked to Treatment-Free Remission in Patients With CML?
Use of Live Attenuated Vaccines in Teenagers Treated With Imatinib for CML
TKI Therapy for CML and Cardiovascular Adverse Events
Nilotinib for Chronic Phase CML: Japanese Dose-Escalation Study
Considerations for Using Tyrosine Kinase Inhibitors in CML During the COVID‐19 Pandemic
DDW 2020: Platelet Threshold and Adverse Events After Endoscopy in SCT Recipients
Combining Venetoclax and TKI in Ph-Positive Advanced Myeloid Leukemias
Long-Term Survival Outcomes With Front-Line Dasatinib in CML
Body Mass Index and Dasatinib for Chronic Phase CML
How COVID-19 May Affect Patients on TKI Therapy for Chronic Myeloid Leukemia
CML and COVID-19: ASH Offers Answers to Frequently Asked Questions
Ruxolitinib for Rare BCR-ABL1–Negative Myeloid Neoplasms

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.